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Objectives: To investigate the effect of tramadol on performance during a 20-min cycling time-trial 3 
(Experiment 1), and to test whether sustained attention would be impaired during cycling after tramadol 4 
intake (Experiment 2). 5 
Design: randomized, double-blind, placebo controlled trial. 6 
Methods: In Experiment 1, participants completed a cycling time-trial, 120-min after they ingested either 7 
tramadol or placebo. In Experiment 2, participants performed a visual Oddball task during the time-trial. 8 
Electroencephalography measures (EEG) were recorded throughout the session. 9 
Results: In Experiment 1, average time-trial power output was higher in the tramadol vs. placebo 10 
condition (tramadol: 220 watts vs. placebo: 209 watts; p < 0.01). In Experiment 2, no differences between 11 
conditions were observed in the average power output (tramadol: 234 watts vs. placebo: 230 watts; p > 12 
0.05). No behavioural differences were found between conditions in the Oddball task. Crucially, the time 13 
frequency analysis in Experiment 2 revealed an overall lower target-locked power in the beta-band (p < 14 
0.01), and higher alpha suppression (p < 0.01) in the tramadol vs. placebo condition. At baseline, EEG 15 
power spectrum was higher under tramadol than under placebo in Experiment 1 while the reverse was 16 
true for Experiment 2. 17 
Conclusions: Tramadol improved cycling power output in Experiment 1, but not in Experiment 2, which 18 
may be due to the simultaneous performance of a cognitive task. Interestingly enough, the EEG data in 19 
Experiment 2 pointed to an impact of tramadol on stimulus processing related to sustained attention. 20 
Trial registration: EudraCT number: 2015-005056-96. 21 
.H\ZRUGV 22 
Doping in Sport; Opioid Analgesic; Athletes; EEG; Exercise, Brain  23 
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Introduction 24 
There is an increasing tendency to treat minor sporting injuries with the use of analgesic drugs 25 
in order that an athlete is able WRFRQWLQXHWUDLQLQJDQGFRPSHWLQJ2QHRIWKHVH³WUHQGLQJ´26 
analgesics is tramadol that is an opioid agonist and is used in the treatment of moderate to 27 
severe pain. Tramadol has a dual mechanism of action, being both an µ-opioid receptor agonist, 28 
and a serotonin and norepinephrine reuptake inhibitor 1. Activation of the µ-opioid receptor 29 
agonist can cause analgesia and sedation. Likewise, by inhibiting serotonin and norepinephrine 30 
reuptake, tramadol seems to reduce pain perception 1. Given the negative association between 31 
pain and exercise capacity, the prophylactic use of analgesic medication (also known as 32 
SDLQNLOOHUV´LVUHODWLYHO\FRPPRQWRUHGXFHSDLQLQRUGHUWRHQKDQFHVSRUWSHUIRUPDQFH2. 33 
Similar to other painkillers 3, it is therefore possible that tramadol could improve exercise 34 
performance via its effect on effort, pain perception, or mood. However, little is known about 35 
the effect of tramadol in sporting performance, with the literature being limited to non-athletic 36 
populations 4. Of the limited research to date, results are conflicting with some suggesting 37 
beneficial effects of reduced pain perception and improved effort based exercise performance 4, 38 
some reporting uncertain effects on cognitive function 5, and some proposing a negative effect 39 
on cognitive function and chemosomatosensory evoked potentials 6. 40 
Informal reports from professional World-Tour cyclists and staff suggest that there may be 41 
some abuse of tramadol for potential performance enhancement reasons 7. Indeed, results of a 42 
recent study involving young elite cyclist suggested that they identified tramadol as a potential 43 
doping agent 8. Despite a significant media interest surrounding tramadol 9, little is known of its 44 
ergogenic effect in cycling. Currently, tramadol is not included on the list of banned substances 45 
by the World Anti-GRSLQJ$JHQF\:$'$EXWLWLVSODFHGRQ:$'$¶VPRQLWRULQJSURJUDP46 
from 2012 to 2017 to detect potential patterns of abuse 10. According to the WADA monitoring 47 
program, 71 to 82 percent of the tramadol use between 2012 and 2015 in globally monitored 48 
sports occurred in cycling 11. Of particular concern is the drowsiness reported following 49 
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tramadol administration, which could lead to reduced perception, attention and vigilance 50 
causing possible falls in the pro-cycling peloton 12. 51 
In this study, we aimed to test the potential ergogenic effect of tramadol during cycling, and 52 
whether it reduces sustained attention (i.e. the ability to keep focused on a particular task over 53 
the time). Sustained attention was investigated at the behavioural and brain level, by asking 54 
participants to perform a cognitive task while performing the cycling exercise and by recording 55 
electroencephalography (EEG). Specifically, we tested the hypothesis that acute oral 56 
administration of tramadol would improve 20-min cycling time-trial performance (Experiment 57 
1). We hypothesised that information processing and behavioural responses in a sustained 58 
attention task would be influenced by tramadol during the 20-min time-trial (Experiment 2). 59 
Given the aforementioned effect of painkillers on perceptual variables 3, we also investigated 60 
subjective measures of the SDUWLFLSDQWV¶mood, perceived effort and mental fatigue. We 61 
hypothesised that tramadol would affect mood at rest and reduce perceived effort and fatigue 62 
during the 20 min TT. 63 
Methods 64 
The study involved a randomized, double blind, placebo controlled trial. The trial was approved 65 
by the Spanish Agency of Medicines and Medical Devices (AEMPS), EudraCT number: 2015-66 
005056-96, and the Ethical Committee of Clinical Research in Granada. All experimental 67 
procedures were designed to comply with the Declaration of Helsinki and Good Clinical 68 
Practice (GCP). The randomization process, the audit and verification of compliance of GCP 69 
rules were performed by an external clinical research organization (CRO; Delos Clinical, 70 
Seville, Spain). The sample sizes were based on power calculations using G*Power Software 13 71 
and assuming a 0.8 power and an alpha error of 0.05. Only cyclists and triathletes with a high-72 
medium level of physical fitness were included in the study. Exclusion criteria were the 73 
presence of symptomatic cardiopathy, metabolic disorders such as obesity (BMI >30) or 74 
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diabetes, chronic obstructive pulmonary disease, epilepsy, therapy with ß-blockers and 75 
medications that would alter cardiovascular function, hormonal therapy (and estrogen-76 
progestogen contraception for females participants) and smoking. Participants were asked to 77 
refrain from drinking alcohol (48 h abstinence) and caffeine (24 h abstinence), to keep their pre-78 
exercise meal the same, and not to perform any exhaustive exercise in the 48 h before each 79 
experimental visit. 80 
In Experiment 1, we recruited 30 cyclists, 20 males and 10 females. Two participants could not 81 
complete Experiment 1: one male due to nausea and drowsiness after tramadol ingestion 82 
(approximately 90min), and one female due to an ankle injury not related with the experiment. 83 
The final sample was 28 participants, 19 males and 9 females, (mean (SD) age 25.6 (5.9) years, 84 
weight 69.07 (10.3) Kg; VO2max: 49.17 (7.29 ml/min/kg) for Experiment 1. For male 85 
participants, tramadol dose corresponded to 1.35 mg/BM, with a dose of 1.77 mg/BM given to 86 
females. Participants visited the research laboratory on three separate occasions at the Mind, 87 
Brain and Behaviour Research Centre of the University of Granada, firstly for an assessment of 88 
their cardiorespiratory fitness, with two further visits for the experimental manipulation. At 89 
initial visit participants performed a maximal incremental exercise test to establish their 90 
maximal oxygen uptake following a standard laboratory protocol 14. During the test, 91 
participants¶ VO2 was measured on a breath-by-breath basis using an online gas analyser 92 
(JAEGER MasterScreen; CareFusion GmbH, Germany). After completing the maximal 93 
incremental test, participants performed a 10-minutes time-trial in order to familiarised with 94 
protocol. The shorter duration of the familiarization test (with respect to the proper experimental 95 
time-trial) might be seen as a limitation of our study. However, two reasons motivated our 96 
choice: 1) our participants were experienced cyclists used to performing this type of (sustained) 97 
physical effort, and given their expertise, the purpose was that of familiarize them with the 98 
laboratory setting testing procedure, 2), we were mindful that the ¶WHVWZDVSHUIRUPHGDIWHU99 
the maximal incremental exercise test from which participants were already fatigued. 100 
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On arrival at the laboratory for visit 2 and 3 (supplementary material Fig 1 for protocol 101 
schematic), participants completed a Profile of Mood States Questionnaire (POMS), and a 102 
visual analogue scale (VAS) concerning perceived activation, mental and physical fatigue. After 103 
completing the questionnaires, participants consumed either tramadol or placebo as outlined 104 
below. The experimental sessions were completed at the same time of the day (±1 h). The time-105 
trial commenced 120 min following ingestion of the tramadol or placebo capsule (see 106 
experimental manipulation below). Before the beginning of the time-trial, the participant¶s EEG 107 
was recorded as a baseline measure and throughout the session. Next, participants performed a 108 
10 min warm-up at 100 watts, followed immediately by a 20-min cycling time-trial on a cycle 109 
ergometer (SRM, Julich, Germany). Participants adjusted saddle and handle bar height and 110 
length, and it was kept for all sessions. The time-trial was conducted in a dimly-illuminated, 111 
sound-attenuated faraday cage. Convective cooling was provided by one fan (2.5 m/s wind 112 
speed) located 100cm from the ergometer. Participants were instructed to maintain the highest 113 
average power possible during the time-trial and were freely able to change gearing and cadence 114 
throughout. Participants were aware of the elapsed time, but did not have feedback on 115 
performance (wattage and heart rate) during, or after the time-trial. Heart rate was measured 116 
continuously throughout the protocol (V800, Polar Electro, Finland). Immediately after the 117 
time-trial participants were asked to rate their average perceived exertion during the preceding 118 
exercise. Then, participants completed 10 min cool-down (60 watts), following which another 119 
EEG recording was taken. Finally, the POMS and VAS were completed again. 120 
As we did not find any effect of gender in Experiment 1, and given the difficulty of finding a 121 
large enough samples of females, we only recruited and tested males and in Experiment 2. One 122 
participant only completed visit 1, and data from another was removed due to data acquisition 123 
issues, meaning that the final sample for Experiment 2 was n = 28: age 25 (5) years, weight 73.2 124 
(7.7) Kg; VO2max: 54.1 (5.7) ml/min/kg. The procedure of the Experiment 2 was the same as that 125 
of Experiment 1, except for the following: participants completed an oddball sustained attention 126 
task during the 20-min time-trial with the purpose of assessing sustained attention during 127 
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exercise. Participants completed a visual three-stimulus oddball paradigm based on that used by 128 
Sawaki and Katayama 15 while performing the 20-min time-trial.  129 
Participants consumed either a single oral dose of 100 mg of tramadol or placebo 130 
(microcrystalline cellulose) with water. The tramadol dose used in this study has been 131 
demonstrated to have effect on µ-opioid receptor (compared with placebo), with a mean time to 132 
maximum plasma concentration of 156 min (range: 87-208 min; 1). Importantly, Bastami et al. 133 
1
, showed good tolerability to adverse events with this dose. The Hospital Pharmacology 134 
Section of the University of Granada prepared the tramadol and placebo oral doses. Tramadol 135 
and placebo were made following the good manufacturing practice (GMP) audited and 136 
approved by Spanish authority (AEMPS). The randomization was performed on a 1:1 balanced 137 
allocation where a code was assigned for tramadol and placebo to each patient in different visit 138 
order. Only a pharmacist who was not involved in the experimental work of this study knew the 139 
participant randomization. Tramadol and placebo were made in dark red hard gelatine capsules, 140 
which prevented the possibility to see the contents. Each capsule was packed in a monodose 141 
blister with the patient code and visit number in the information label. No less than 7 days were 142 
allowed between experimental sessions to allow for washout time and recovery.  143 
We used the Spanish adapted version of the POMS 16, which has been used extensively for the 144 
assessment of mood in the sport and exercise environments. This questionnaire has 58 items and 145 
the factor structure representing six dimensions of the mood construct: Tension, Depression, 146 
Anger, Vigour, Fatigue and Confusion. Participants answered the items on a 5-point Likert scale 147 
(0 = not at all, 1 = a little, 2 = moderately, 3 = quite a bit, 4 = extremely). Raw scores were 148 
transformed following the standard point table 16. 149 
The VAS to rate SDUWLFLSDQWV¶ perceived activation, perceived mental and physical fatigue, 150 
ranging from 0 (low) to 100 (highLQUHVSRQVHWRWKHIROORZLQJTXHVWLRQVD³:KDWLV\RXU151 
DFWLYDWLRQOHYHOQRZ"´E³:KDWLV\RXUSK\VLFDOIDWLJXHOHYHOQRZ"´DQGF³:KDWLV\RXU152 
mental fatigue level now? At the end of the session, participants also rated the following 153 
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TXHVWLRQ³KRZ ZRXOG\RXUDWHWKHRYHUDOOPHQWDOORDGIRUWKLVH[SHULPHQWDOVHVVLRQ"´154 
Immediately after the time-trial participants were asked to rate their average perceived 155 
exhaustion (RPE) using the 6-20 Borg scale.  156 
An oddball task was designed to measure sustained attention by the random presentation of a 157 
VHTXHQFHRIYLVXDOVWLPXOLRQDFRPSXWHUVFUHHQVLWXDWHGDWFPIURPWKHSDUWLFLSDQWV¶KHDG158 
and at their eye level. A total of 600 stimuli were presented, consisting of frequent blue circle, 159 
rare blue circle, and rare red square with probabilities of .80, .10, and .10, respectively via use 160 
of computer software (E-Prime, Psychology Software Tools, Pittsburgh, PA, USA). The task 161 
lasted approximately 18 minutes, starting two minutes after the beginning of the time-trial. The 162 
small blue circle (1.15º x 1.15º) was considered as the standard stimulus. The blue circle that 163 
was slightly larger than the standard circle (1.30º x 1.30º) was defined as target 1. Finally, the 164 
rare red square (2.00º x 2.00º) was defined as target 2. Each trial begun with the presentation of 165 
a blank screen in a black background for 1200 ms. Then, the stimulus was presented in the 166 
centre of the screen in a random time interval (between 0 and 800 ms) during 150 ms 167 
(supplementary material Fig 2). Participants were required to respond to both target 1 and target 168 
2 with their thumb finger of their dominant hand by pressing a button connected to the cycle 169 
ergometer handlebar, and not to respond to the standard stimuli. Verbal and written instructions 170 
were given to the participant prior to the start of the oddball sustained attention task. 171 
Participants were instructed that the main goal of the task was to be as accurate as possible. A 172 
brief familiarization of the task was included in the screening visit. For each stimulus, the RT 173 
(in ms) and response accuracy (percentage of correct responses) were recorded. 174 
At this point, we would like to note that, while the POMS used in the present study has shown a 175 
high reliability (Cronbach alpha = 0.90) 16, we do not have a measure of reliability for the 176 
particular VAS and oddball tasks used in our study. The lack of reliability may suppose a 177 
limitation in the present investigation, but, generally, oddball tasks show an interclass 178 
correlation coefficient higher than 0.75 17, and the VAS a Cronbach alpha higher than 0.90, 179 
showing high test-retest reliability 18,. In any case, the purpose of these tasks were to compare 180 
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performance in within-participants experimental conditions and not to compare SDUWLFLSDQWV¶181 
scores with a normalized scale. 182 
EEG data were recorded at 1000 Hz using a 62-channel actiCHamp System (Brain Products 183 
GmbH, Munich, Germany) with active electrodes positioned according to the 10-20 EEG 184 
International System and referenced to the Cz electrode. The cap was adapted to individual head 185 
size, and each electrode was filled with Signa Electro-Gel (Parker Laboratories, Fairfield, NJ) to 186 
optimize signal transduction. Participants were instructed to avoid body movements as much as 187 
possible, and to keep their gaze on the centre of a computer screen during the measurement. 188 
(OHFWURGHLPSHGDQFHVZHUHNHSWEHORZNȍ((*SUH-processing was conducted using 189 
custom Matlab scripts and the EEGLAB 19 and Fieldtrip 20 Matlab toolboxes. EEG data were 190 
resampled at 500 Hz, bandpass filtered offline from 1 and 40 Hz to remove signal drifts and line 191 
noise, and re-referenced to a common average reference. Horizontal electrooculograms (EOG) 192 
were recorded by bipolar external electrodes for the offline detection of ocular artefacts. 193 
Independent component analysis was used to detect and remove EEG components reflecting eye 194 
blinks 21.  195 
Electrodes presenting abnormal power spectrum were identified via visual inspection and 196 
replaced by spherical interpolation. Processed EEG data from each protocol time period 197 
(baseline-pre, warm-up, time-trial, cool-down, baseline-post) were subsequently segmented to 198 
1-s epochs. The spectral decomposition of each epoch was computed using Fast Fourier 199 
Transformation (FFT) applying a symmetric Hamming window and the obtained power values 200 
were averaged across protocol time periods. 201 
Task-evoked spectral EEG activity was assessed by computing event-related spectral 202 
perturbations in epochs extending from ±500 ms to 500 ms time-locked to stimulus onset for 203 
frequencies between 4 Hz and 40 Hz. Spectral decomposition was performed using sinusoidal 204 
wavelets with 3 cycles at the lowest frequency and increasing by a factor of 0.8 with increasing 205 
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IUHTXHQF\3RZHUYDOXHVZHUHQRUPDOL]HGZLWKUHVSHFWWRDíPVWRPVSUH-stimulus 206 
baseline and transformed into the decibel scale (10*log10 of the signal). 207 
All analyses were completed using statistical non-parametric permutation tests with a Monte 208 
Carlo approach 22. These tests do not make any assumption of the underlying data distribution, 209 
are unbiased, and as efficient and powerful as parametric statistics 23. When statistical 210 
significance (p < 0.05) was found, values were corrected by the false discovery rate method. 211 
Subsequently, the effect of experimental condition (tramadol vs. placebo) on: Experiment 1 - 212 
cycling time trial power output and heart rate; and Experiment 2 - cycling time trial power 213 
output, heart rate, and RT and accuracy in the oddball task were analysed using a within-subject 214 
design condition (tramadol, placebo). Data from POMS, and VAS, were analysed using a 215 
condition (tramadol, placebo) and time point (pre, post) within-subject design.  216 
EEG spectral power main effects of condition (tramadol, placebo) were separately tested for 217 
significance at each protocol time period. In the absence of strong a priori hypotheses, we used 218 
a stepwise, cluster-based, non-parametric permutation test 24 without prior assumptions on any 219 
frequency range or area of interest. The algorithm performed a t-test for dependent samples on 220 
all individual electrodes x frequencies pairs and clustered samples with positive and negative t-221 
values that exceeded a threshold based on spatial and spectral adjacency. These comparisons 222 
were performed for each frequency bin of 1Hz and for each electrode without a priori 223 
assumptions on the frequency range or region of interest. Cluster-level statistics were then 224 
calculated by taking the sum of the t-values within each cluster. The trials from the two datasets 225 
(tramadol, placebo) were randomly shuffled and the maximum cluster-level statistic for these 226 
new shuffled datasets was calculated. The above procedure was repeated 5000 times to estimate 227 
the distribution of maximal cluster-level statistics obtained by chance. The two-tailed Monte-228 
Carlo p-value was determined by the proportion of random partitions that resulted in a larger 229 
test statistic than the original. A p-value of the original cluster statistic smaller than the critical 230 
Monte-Carlo p-value indicated significant differences between the two datasets. 231 
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In Experiment 2, event-related spectral perturbation main effects of condition (tramadol, 232 
placebo) for each stimulus of the odd-ball task (target 1, target 2 and standard) were also 233 
analysed by applying the cluster-based permutation test. In order to reduce the possibility that 234 
the type II error rate was inflated by multiple comparisons correction, we set a priori criteria of 235 
collapsing data into four frequency bands: Theta (4±8 Hz), Alpha (8±14 Hz), lower Beta (14±20 236 
Hz) and upper Beta 1 (20±40 Hz). To avoid an overlap with behavioural responses, we also 237 
limited the time windows of interest to the first 300 ms and 500 ms after the stimuli onset 238 
(based on average behavioural response times) for target and standard trials, respectively.  239 
Results  240 
In Experiment 1, the average power output during the 20-min time-trial (Fig 3A) was 241 
higher under tramadol condition than under placebo condition (220 W [95%CI = 203 ± 240 W] 242 
vs. 209 W [95%CI = 192 ± 228W] for tramadol and placebo, respectively; p < 0.01). An 243 
additional analysis UHYHDOHGWKDWWKHHIIHFWRIWUDPDGROGLGQRWGHSHQGRQSDUWLFLSDQWV¶JHQGHUW244 
= 1.107, p = 0.83 (critical t-score: ± 2.177).  245 
The average heart rate demonstrated a significant difference between conditions (166 beats.min-246 
1
 [95%CI = 162 ± 170 beats.min-1] vs. 162 beats.min-1 [95%CI = 153± 166 beats.min-1] for 247 
tramadol and placebo, respectively; p < 0.01).  248 
The POMS data demonstrated a significant interaction between condition and time point for 249 
fatigue (p = 0.03), confusion (p < 0.01) and tension (p < 0.01). Under the tramadol condition, 250 
participants showed a higher fatigue (M = 52, 95%CI = 48 - 55 vs. M = 47, 95%CI = 44 - 49); p 251 
< 0.01) and confusion (M = 41, 95%CI =38 - 44 vs. M = 38, 95%CI = 36 - 39); p < 0.01) after 252 
the time-trial, while no difference where found before the time-trial for fatigue (M = 42, 95%CI 253 
= 39 - 45 vs. M = 40, 95%CI = 38 - 42), p > 0.05) and for confusion (M = 39, 95%CI = 37 - 40 254 
vs. M = 38, 95%CI = 37 - 39); p < 0.05). There were trends for lower tension before (M = 35, 255 
95%CI = 33 - 37 vs. M = 38, 95%CI = 35 - 39) tramadol vs. placebo, respectively; p = 0.06), 256 
but not after the time-trial (M = 35, 95%CI =32 - 36 vs. M = 34, 95%CI = 32 - 35), for tramadol 257 
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and placebo, respectively; p > 0.05). The anger index showed a main effect for time point (p < 258 
0.01) with higher values before the time-trial (M = 38, 95%CI = 37 ± 40 vs. M = 39, 95%CI = 259 
36 ± 39), but no effect for condition or interaction between the factors. No other POMS factors 260 
(depression and vigour) demonstrated significant changes with condition or time point (ps > 261 
0.05). 262 
Post time-trial RPE did not demonstrate any significant differences between conditions (p > 263 
0.05). VAS Mental Load demonstrated a trend for an interaction between condition and 264 
measure. Specifically, after the time-trial participants had trend for a higher mental fatigue in 265 
the tramadol vs. placebo condition (M = 34, 95%CI = 24 - 44 vs. M = 22, 95%CI =16 - 28), 266 
respectively; p = 0.056). The main effect for time point was not significant (p > 0.05).  267 
The Activation and Fatigue indexes demonstrated a significant main effect of time point 268 
(Activation: M = 51, 95%CI = 44 - 57 vs. M = 60, 95%CI = 54 - 66; p < 0.01. Fatigue: M = 21, 269 
95%CI = 13- 28 vs. M = 45, 95%CI = 36 - 52; p < 0.01). Before vs. after the time-trial 270 
respectively), while the main effect for condition and the interaction between both factors did 271 
not reach significance (p > 0.05). Finally, the cognitive load of the session was not significantly 272 
different between conditions (p > 0.05). 273 
The analysis of tonic spectral power showed a significant main effect of condition (p < 0.01) for 274 
the baseline period. One cluster (frequency-localization) was found and was statistically 275 
significant: a global cluster (51 electrodes) in the beta band (13-40 Hz). The analysis revealed 276 
an overall increase in the power of frequencies in the tramadol condition with regard to the 277 
placebo (supplementary material Table 1). 278 
There was a significant main effect of condition (p = 0.01) for the warm-up period. One cluster 279 
was statistically significant: a 33 electrodes cluster in the alpha band (7-10 Hz). The analysis 280 
revealed an overall increase in the power of frequencies in the tramadol condition in comparison 281 
to the placebo condition. There were no statistically significant terms in the analysis of the EEG 282 
data from the time-trial, cool-down and baseline-post phases (p > 0.05). 283 
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In Experiment 2, one participant only completed visit 1, and data from another was 284 
removed to due data acquisition issues meaning that the final sample was n = 28 for Experiment 285 
2. The power output during the time trial was not significantly different between conditions see 286 
(Fig 3B): tramadol (234 W [95% CI = 218± 248 W]) vs. placebo (230 W [95%CI = 215± 246 287 
W] p > 0.05).  288 
The main effect of condition did not reach statistical significance for the heart rate: tramadol 289 
176 beats.min-1 [95%CI = 172 ± 179] vs. placebo (175 beats.min-1 [95%CI = 170 ± 179]; p > 290 
0.05.  291 
Analysis of the POMS demonstrated a main effect of time point for the factor anger and fatigue 292 
(p < 0.05). Participants showed lower anger (M = 42, 95%CI = 40 - 44 vs. M = 40, 95%CI = 38 293 
- 42) and higher fatigue (M = 44, 95%CI = 41 - 46 vs. M= 51 95%CI = 48 - 53), after the time-294 
trial. None of the other POMS items reached statistical significance (p > 0.05). 295 
There were no differences in post time-trial RPE between conditions (p > 0.05). An overall 296 
main effect of time point was found for fatigue and mental load in the VAS. Specifically, a 297 
higher mental fatigue (M = 31, 95%CI = 21 - 40 vs. M = 54, 95%CI = 47 - 60; p < 0.01) and 298 
higher mental load (M = 25, 95%CI = 17 ± 32 vs. M = 44, 95%CI = 36 - 52; p < 0.01) were 299 
found after the time-trial. None of the others items in the analysis reached significance (p > 300 
0.05). 301 
In the Oddball task, there were no significant differences between conditions for the target1, 302 
target2 or standard stimuli, for RT and accuracy (all ps > 0.05).  303 
The analysis of tonic spectral power revealed a significant main effect of condition (p < 0.01) 304 
for the baseline-pre period. One cluster (frequency-localization) was found and was statistically 305 
significant: a global cluster (41 electrodes) in alpha band. The analysis revealed an overall 306 
increase in the power of frequencies in the placebo condition with regard to tramadol. There 307 
was a significant main effect of condition (p < 0.01) in the warm-up period. Two clusters were 308 
 13 
statistically significant: one cluster (17 electrodes) in the 3-6 Hz band (p = 0.01), and one cluster 309 
(5 electrodes) in the 26±33 Hz band (p = 0.02). The analysis revealed an overall increase in the 310 
power of frequencies in the placebo condition in comparison to the tramadol condition (Table 311 
1). 312 
The main effect of condition during the time-trial was not significant (p>0.05). There was a 313 
significant main effect of condition (p < 0.05) for the cool-down period. Two clusters were 314 
statistically significant: one cluster (29 electrodes), in the (1±9 Hz) delta and theta band (p < 315 
0.01); and one global cluster (41 electrodes) in (12±36 Hz) beta band (p < 0.01). Similar to other 316 
period, the analysis revealed an overall increase in the power of frequencies in the placebo 317 
condition. In the baseline-post period we found a main effect of condition. One cluster was 318 
found (29 electrodes) and was statistically significant (p = 0.01) in the theta band. Similar to 319 
other periods, the analysis showed an increase in the power for placebo compared to tramadol.  320 
The event-related spectral perturbation (stimulus-locked) analysis in Experiment 2 showed a 321 
main effect of condition in the alpha band for target 1, with a cluster (15 electrodes) between 322 
118-224 ms after the onset of the target 1 (p < 0.01; see Fig 4 A- B). Alpha frequency band 323 
exhibited a lower spectral power in the tramadol condition with regard to the placebo condition. 324 
The Lower Beta band analysis showed a significant cluster (24 electrodes) between 136-230 ms 325 
after the onset of target 1 (p < 0.01). Lower Beta frequency band exhibited a higher spectral 326 
power in placebo condition with regard to the tramadol condition (see Fig 4C). The analysis of 327 
the other frequency bands for target 1, target 2 and standard trials yielded no significant effects 328 
(p > 0.05). 329 
Discussion 330 
To the best of our knowledge, this is the first study to investigate the effect of tramadol on 331 
cycling performance, sustained attention and brain dynamics in trained cyclists. Data from 332 
Experiment 1 revealed that tramadol improved 20-min cycling time-trial performance by ~5%. 333 
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In contrast, there was no difference in average power output between tramadol and placebo 334 
condition in Experiment 2. Although no effect of tramadol was found on behavioural 335 
performance in the sustained attention tasks, EEG time-frequency (stimulus-locked) analysis 336 
showed effects of tramadol on brain functioning related to stimulus processing.  337 
Tramadol allowed participants to sustain a higher power and greater cardiorespiratory stress 338 
(higher heart rate) during the 20-min time-trial than in the placebo condition in Experiment 1. 339 
However, the RPE following the time-trial was similar between both substance conditions. 340 
Similar results have been reported with other analgesics. For instance, previous research has 341 
shown that paracetamol improves performance in a 10-mile cycling time trial compared to 342 
placebo in the absence of a reduction in perceived pain or perceived exertion 3. In another study, 343 
Foster et al. 25, also found that paracetamol improved performance compared to placebo. 344 
However, in this study testing repeated sprint ability, the authors concluded that paracetamol 345 
increased the level of performance due to an increase in SDUWLFLSDQW¶V normal pain threshold. In 346 
the present study, although no differences were found in perceived exertion, we cannot ensure 347 
that pain perception was modulated by tramadol, since we did not ask participants to rate it. 348 
Interestingly, in Experiment 2, the effect of tramadol on time-trial power output was not 349 
significant. The reason for these divergent results between Experiment 1 and 2 is uncertain (see 350 
below for further discussion on this issue).  351 
We only found an effect of tramadol on the POMS items for confusion and fatigue in 352 
Experiment 1. In both cases, participants showed a higher score after the time-trial with 353 
tramadol. However, it is uncertain whether tramadol caused higher fatigue and confusion, or 354 
whether these higher rating were a consequence of the greater physical effort achieved during 355 
the time-trial.  356 
The oddball task was chosen to test the hypothesis of whether tramadol may impair cognitive 357 
function during cycling. This oddball task WHVWVSDUWLFLSDQW¶VDELOLW\WRdiscriminate between a 358 
standard (frequent and irrelevant) and target (rare and infrequent) stimuli 15. These continuous 359 
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discriminations between monotonous frequent information and relevant infrequent stimuli are 360 
characteristic of those encountered in a cycling peloton (e.g., avoiding a pothole in the road, or 361 
sudden breaking in front). Our hypothesis was that tramadol would impair attention level and 362 
participants would perform worse in the oddball task. However, RT and accuracy results did not 363 
show significant differences between conditions for any of the stimuli. Nevertheless, EEG data 364 
did reveal an interesting pattern of results in relation to (brain) event-related activity following 365 
tramadol ingestion. 366 
Specifically, there was target-locked higher suppression of the alpha activity (i.e., lower 367 
activity) and overall reduced beta frequency after tramadol intake with respect to the placebo 368 
condition. A previous study using a similar visual oddball task 26 also found a greater alpha 369 
suppression for the odd target stimuli that was interpreted as a higher mental effort to detect 370 
infrequent targets. Hence, in our study, the higher alpha suppression under tramadol condition 371 
may be interpreted as the result of participants allocating more attentional resources than in the 372 
placebo condition (which enabled them to achieve similar behavioural performance). This 373 
higher mental effort may KDYHDIIHFWHGWKHF\FOLVWV¶SK\VLFDOSHUIRUPDQFHduring the time trial, 374 
which might explain the divergent results between Experiment 1 and 2 27 in terms of power 375 
output. Hence, while the cognitive load induced by the oddball task might have interacted with 376 
substance intake, modulating the effect of tramadol on physical performance. 377 
Due to the analgesics properties of tramadol, it might have been expected that EEG amplitude 378 
was greater in alpha and beta bands, since a decrement in attention has been reported after the 379 
overall increase in these bands 28. However, our EEG results present conflicting findings, as 380 
opposite results were found in Experiment 1 and 2. In Experiment 1, we found a higher spectral 381 
(tonic) power in the tramadol condition (at baseline-pre and warm-up), while in Experiment 2, 382 
the power spectral was higher in the placebo condition (at baseline-pre, post, warm-up and cool-383 
down). Indeed, the effect of opioids at the EEG level is not clear in the previous literature as 384 
some have reported an increase in these frequencies band 29, whilst others have found the 385 
opposite effect 6.  386 
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Conclusion 387 
The results of Experiment 1 showed that tramadol improves performance in a 20-min cycling 388 
time-trial, although the failed replication in Experiment 2 points to an influence of a concurrent 389 
cognitive task on the potential manifestation of the tramadol effect at the physical performance 390 
level. Tramadol does not seem to impair (behavioural) cognitive performance in the ability to 391 
maintain attention during exercise, although it may influence information processing as 392 
highlighted by EEG time-frequency data. It appears then that the presence of tramadol on the 393 
:$'$¶VPRQLWRULQJSURJUDP seems reasonable as far as performance enhancement is 394 
concerned. Even though the present findings have to be considered with caution (as this is the 395 
first empirical approach to this issue), they open interesting venues for future research on this 396 
relevant topic.  397 
Practical applications 398 
Tramadol may improve cycling time-trial performance. 399 
Tramadol influences information processing related to sustained attention at the brain level, 400 
although it was not translated into an impaired behavioural performance.  401 
Anti-GRSLQJDXWKRULWLHVPD\UHFRQVLGHUWUDPDGRO¶VVWDWXV 402 
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task. Grand averages are illustrated separately for each condition (tramadol, placebo). The enclosed areas 507 
denote significant clusters of channels and time with p < 0.025. B Main effect in event-related alpha 508 
frequency perturbations time-locked at target 1 of the oddball sustained attention task. Left panel: Non-509 
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shaded areas represent 95% confidence intervals. C Main effect of condition in event-related lower-beta 516 
frequency perturbations time-locked at target 1 of the oddball sustained attention task. Right panel shows 517 
grand average spectral power curves indicating the main effect of condition at the lower-beta frequency 518 
band. The topography depicts t-test distribution across surface localization, showing the 24 electrode sites 519 
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